Technology
Health
Biotechnology

NantKwest

$1.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.08 (-5.97%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NantKwest and other stocks, options, ETFs, and crypto commission-free!

About

NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. Read More The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.

Employees
161
Headquarters
San Diego, California
Founded
2002
Market Cap
99.65M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
298.25K
High Today
$1.38
Low Today
$1.25
Open Price
$1.37
Volume
157.99K
52 Week High
$4.40
52 Week Low
$0.93

Collections

Technology
Health
Biotechnology
Cancer Prevention
2015 IPO
US
North America

News

Simply Wall StMar 15

Does NantKwest, Inc.’s (NASDAQ:NK) CEO Pay Reflect Performance?

Patrick Soon-Shiong has been the CEO of NantKwest, Inc. (NASDAQ:NK) since 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the business demonstrates. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. This process should give us an idea about how appropriately the CEO is paid. Check out our latest analysis for NantKwest How Does Patrick Soon-...

89
MarketBeatMar 5

Stock Price, News, & Analysis for Nantkwest

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer ...

51
Associated PressMar 4

NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics

SAN DIEGO--(BUSINESS WIRE)--Mar 4, 2019--NantKwest, Inc.(Nasdaq:NK), a leading clinical-stage Natural Killer (NK) cell based therapeutics company, and ProMab Biotechnologies today announced the establishment of a worldwide license to a B-Cell Maturation Antigen (BCMA) targeted antibody sequence for multiple myeloma along with an option for up to five undisclosed targeting sequences for exclusive use in the development of chimeric antigen receptor (CAR) based NK cell therapies. “We are pleased to announce t...

198

Earnings

-$0.37
-$0.33
-$0.28
-$0.24
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.24 per share
Actual
Expected Mar 27, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.